Biofrontera Inc. (BFRI) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

56/ 100

GoAI Score

Hold

Valuation

70

Undervalued

Sentiment

52

Mixed

Risk

49

Elevated Risk

Momentum

68

Gaining

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Company website

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Industry: Medical - Pharmaceuticals
Sector: Healthcare
Headquarters: US
CEO: Hermann Lübbert
Listed since: Oct 29, 2021
Employees: 89

Market position

Day range

Current $0.97

$0.9205$0.998

52-week range

Current $0.97

$0.5547$1.66

Open: $0.925
Previous close: $0.9188
Volume: 275.02K; 0.57× average
Average volume: 483.49K; Average daily volume
Market cap: 12.42M USD
Beta: 0.88; Market reference 1
50-day average: $1.2865; -24.60% below average
200-day average: $1.0274; -5.59% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 5.57M USD
P/E (TTM): -1.62×
P/B (TTM): 2.1×
P/S (TTM): 0.27×
EV / EBITDA: -0.61×
Earnings yield: -181.72%
Free cash flow yield: -230.48%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 84.45%
Operating margin: -9.45%
Net margin: -13.78%
Return on equity: -100.53%
Return on assets: -36.89%
Return on invested capital: -53.81%

Financial health

Debt / equity: 1.26×
Current ratio: 1.52×
Altman Z-score: -6.19
Piotroski F-score: 2 of 9

Earnings

Latest fiscal-year EPS: -0.9; FY2025
Latest fiscal-year revenue: 41.71M USD; FY2025 · +11.80% year over year
Next fiscal-year EPS consensus: 0.19; FY2028 · 2 analysts
Next fiscal-year revenue consensus: 68.36M USD; FY2028 · 2 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

BFRI news

globenewswire.comOct 8, 2026

Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body

Submission seeks to extend the Ameluz ® label beyond the face and scalp to treatment fields of up to approximately 240 cm² on the rest of the body, with an adjusted illumination protocol

Read source

defenseworld.netOct 5, 2026

Biofrontera (NASDAQ:BFRI) & Astrazeneca (NYSE:AZN) Critical Contrast

Astrazeneca (NYSE: AZN - Get Free Report) and Biofrontera (NASDAQ: BFRI - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of…

Read source

globenewswire.comSep 14, 2026

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera's…

Read source

seekingalpha.comAug 13, 2026

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

Read source

zacks.comAug 13, 2026

Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates

Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.57 per share a year ago.

Read source

globenewswire.comAug 13, 2026

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy…

Read source

BFRI peers

AMGN

Amgen Inc.

$414.87

+1.82%

GILD

Gilead Sciences, Inc.

$151.17

+2.77%

ISRG

Intuitive Surgical, Inc.

$423.96

+2.06%

VRTX

Vertex Pharmaceuticals Incorporated

$510.08

+1.36%

SNY

Sanofi

$40.07

-0.40%

MRNA

Moderna, Inc.

$225

+14.21%

ETFs holding BFRI

Funds reporting this stock among their holdings, ordered by reported position size.

ETFMarket valueWeightAUMExpense ratioPrice / 1D

Vanguard Extended Market ETFVXF129.87K0.00%95.4B USD0.05%$235+0.80%

Vanguard Extended Market ETFVXF

Market value: 129.87K
Weight: 0.00%
AUM: 95.4B USD
Expense ratio: 0.05%
Price / 1D: $235+0.80%

Biofrontera Inc.

BFRI company overview

Company profile

Biofrontera Inc.

BFRI company overview

GoAI snapshot

Company profile

Market position

Financials

Financial snapshot

Valuation & yield

Profitability & efficiency

Financial health

Earnings

Annual EPS trend

Annual revenue trend

BFRI news

Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body

Biofrontera (NASDAQ:BFRI) & Astrazeneca (NYSE:AZN) Critical Contrast

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

BFRI peers

ETFs holding BFRI

Continue in GoAI

BFRI company overview

Company profile

Market position

BFRI company overview

Company profile

BFRI company overview

Company profile

Market position

BFRI company overview

GoAI snapshot

Company profile

Market position

Financials

Financial snapshot

Valuation & yield

Profitability & efficiency

Financial health

Earnings

Annual EPS trend

Annual revenue trend

BFRI news

Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body

Biofrontera (NASDAQ:BFRI) & Astrazeneca (NYSE:AZN) Critical Contrast

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

BFRI peers

ETFs holding BFRI

Continue in GoAI